I-SceI Activators
I-SceI Activators is a conceptual term that refers to a class of chemicals or agents that might be expected to facilitate the activity of the I-SceI endonuclease, an enzyme that introduces double-strand breaks at specific recognition sites within DNA. Any compounds that could be referred to as I-SceI Activators would likely operate indirectly, such as by affecting the expression, stability, or accessibility of the enzyme to its target DNA sequence. These compounds might function by altering cellular processes or the chromatin state, thereby indirectly enabling or augmenting the action of I-SceI. For example, agents that modify chromatin structure to make DNA more accessible, or those that inhibit DNA repair pathways, could potentially increase the number of I-SceI-mediated cleavage events by prolonging the enzyme's substrate engagement or by preventing the rapid repair of cleaved DNA, respectively.
The study of I-SceI Activators would primarily concern molecular biology and biochemistry, focusing on how various compounds can influence the activity of a specific endonuclease within a complex cellular environment. It would involve understanding the cellular pathways that regulate the expression of I-SceI, the mechanisms by which the enzyme identifies and cleaves its target DNA, and how the cell repairs the intentional breaks made by the enzyme. Chemicals that modulate the factors influencing these processes could be considered indirect activators. Such compounds might include DNA-damaging agents that enhance the need for homologous recombination, a repair pathway where I-SceI's activity could be beneficial. Alternatively, they might include inhibitors of histone deacetylases or DNA methylation, which could increase the accessibility of chromatin to I-SceI. Understanding the action of these indirect activators would involve a multidisciplinary approach, combining cellular assays, enzyme kinetics, and studies of gene expression and DNA repair.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lomeguatrib | 192441-08-0 | sc-362764 sc-362764A | 10 mg 50 mg | $205.00 $865.00 | ||
A potent inhibitor of O6-methylguanine-DNA methyltransferase (MGMT), which repairs O6-methylguanine, a form of DNA damage. By inhibiting MGMT, lomeguatrib can enhance the persistence of DNA lesions, potentially increasing the substrate availability for I-SceI. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
A PARP inhibitor that impairs the repair of single-strand breaks, leading to double-strand breaks (DSBs). These DSBs may elevate the recruitment and action of DSB repair machinery, including homologous repair pathways where I-SceI can be functionally active. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
A histone deacetylase inhibitor which causes chromatin remodeling, making DNA more accessible. This increased accessibility may enhance the ability of I-SceI to locate and cleave its recognition site within the genome. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
A topoisomerase II inhibitor that leads to DNA breaks. The resulting DNA damage can stimulate the DNA damage response pathways, potentially increasing the activity of DNA repair enzymes, including homing endonucleases like I-SceI. | ||||||
ATM Kinase Inhibitor | 587871-26-9 | sc-202963 | 2 mg | $110.00 | 28 | |
An ATM inhibitor that prevents the repair of DSBs. By inhibiting ATM, KU-55933 may increase the persistence of DSBs, which could require the activity of endonucleases such as I-SceI to resolve during DNA repair processes. | ||||||
NU 7441 | 503468-95-9 | sc-208107 | 5 mg | $357.00 | 10 | |
A DNA-PKcs inhibitor that hampers non-homologous end joining (NHEJ), a direct DSB repair pathway. Inhibition of NHEJ can shift the repair preference toward homologous recombination, potentially increasing the activity of endonucleases like I-SceI. | ||||||
MRN-ATM Pathway Inhibitor, Mirin | 299953-00-7 | sc-203144 | 10 mg | $141.00 | 4 | |
An MRE11 inhibitor that disrupts the MRN complex, a key player in DSB repair. This disruption can lead to an increased reliance on alternative DSB repair mechanisms, potentially involving endonucleases such as I-SceI. | ||||||
VE 821 | 1232410-49-9 | sc-475878 | 10 mg | $360.00 | ||
An ATR inhibitor that disrupts the response to replication stress and DSBs. By inhibiting ATR, VE-821 may prolong the presence of DSBs, potentially increasing the need for repair enzymes like I-SceI. | ||||||
PARP Inhibitor VIII, PJ34 | 344458-15-7 | sc-204161 sc-204161A | 1 mg 5 mg | $58.00 $142.00 | 20 | |
A PARP inhibitor that, similar to Olaparib, can lead to the accumulation of DSBs. This could indirectly increase the functional activity of I-SceI by enhancing the need for its endonuclease activity during DNA repair. | ||||||
CPI-613 | 95809-78-2 | sc-482709 | 10 mg | $131.00 | 4 | |
A lipoate analog that disrupts mitochondrial metabolism and thereby induces cellular stress, possibly leading to DNA damage and the activation of repair pathways in which I-SceI could play a role. | ||||||